Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01804686 · ClinicalTrials.gov registry record · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
A Phase 3 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 700
- Enrollment target
- 20
- Study locations
NCT01804686 is a Phase 3 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 700 participants, above the 178-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (293% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT01804686, a Phase 3 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 700 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.
Conditions Studied
Interventions
- DRUG Ibrutinib
Study Locations (20)
California
- City of Hope Cancer Center - Duarte
- University of California San Diego Medical Center - La Jolla
- University of California Los Angeles - Los Angeles
- St. Joseph Hospital Center for Cancer Prevention and Treatment - Orange
- Stanford University Medical Center - Stanford
- Stanford University - Stanford
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- Battle Creek Health Systm - Battle Creek
- Karmanos Cancer Institute - Wayne State University - Detroit
Connecticut
- Norwalk Medical Group - Norwalk
Georgia
- Northwest Georgia Oncology Centers PC - Marietta
Illinois
- Northwestern University Hospital - Chicago
Indiana
- Indiana University - Goshen
Kansas
- Kansas University Medical Center - Westwood
Kentucky
- Louisville Oncology Suburban - Norton Cancer Institute - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2013-09-09 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01804686
The ClinicalTrials.gov registry entry for NCT01804686 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 178-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (293% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Ibrutinib is the first listed.
NCT01804686 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Michigan, Connecticut.
Frequently Asked Questions
What is clinical trial NCT01804686 about?
NCT01804686 is a clinical study titled "A Long-term Extension Study of PCI-32765 (Ibrutinib)". The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively recei...
What is the current status of trial NCT01804686?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2013-09-09. Estimated completion is 2027-08-31.
What conditions does trial NCT01804686 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma.
What interventions are being tested in trial NCT01804686?
The interventions under investigation include: Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT01804686?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01804686 being conducted?
This trial has 20 study locations across California, Connecticut, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
RECRUITING · Phase 3
-
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 3
-
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
RECRUITING · Phase 3
-
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
RECRUITING · Phase 3
-
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
RECRUITING · Phase 3
-
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RECRUITING · Phase 3
Explore more on PlainTrial
Chronic Lymphocytic Leukemia
All registered trials for this condition
Diffuse Large B Cell Lymphoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.